Primary Vitreoretinal Lymphoma Mimicking Refractory Uveitis with Spontaneous Regression: A Case Report
Introduction: Primary vitreoretinal lymphoma (PVRL) is a rare and aggressive subtype of primary central nervous system lymphoma (PCNSL) that frequently masquerades as refractory uveitis. The disease is notorious for its high rate of central nervous system dissemination, traditionally requiring prompt and aggressive chemo-immunotherapy. Case Presentation: We report an atypical case of a 75-year-old Chinese man presenting with steroid-refractory uveitis for over three years. A diagnostic vitrectomy confirmed a diffuse large B-cell lymphoma (DLBCL) subtype. Neuro-imaging, including magnetic resonance imaging (MRI) of the brain and orbits, alongside a whole-body positron emission tomography (PET) scan, revealed no systemic or central nervous system involvement. Strikingly, the patient opted for observation rather than systemic chemotherapy or serial intravitreal methotrexate injections. Over a four-year multidisciplinary follow-up period, an intraocular flare-up resolved completely with topical steroids alone. Serial neuro-imaging consistently demonstrated no neuro-oncological progression, indicating an unprecedented spontaneous regression of the intraocular lymphoma. The patient successfully tapered off topical steroids with well-preserved visual acuity and no signs of disease recurrence. Conclusion: This case exceptionally demonstrates that PVRL can exhibit an indolent clinical course and spontaneous regression. It challenges the universally aggressive disease concept of PVRL and highlights that conservative management combined with vigilant, long-term MRI surveillance may be a viable individualized approach for selected patients.
Authors
- Gabriel Ka Hin Li
- Ka Fai To
- Maple Ye Feng
- Mary Ho
- Kenny Ieng Kit Lei
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1159/cro/abzag122
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00